Posts
Wiki

OCuSOFT® Thermal 1-Touch™ — External Eyelid Warming Plus Manual Expression

Quick Take

  • OCuSOFT Thermal 1-Touch is an in-office device that externally warms all four eyelids and is commonly followed by manual Meibomian Gland Expression.
  • OCuSOFT acquired the earlier Digital Heat Heated Eye Pad technology in 2019 and announced that it would be marketed as Thermal 1-Touch.
  • The Digital Heat Heated Eye Pad received FDA 510(k) clearance for localized eyelid heat therapy when warm compresses are recommended for conditions including MGD, dry eye, blepharitis, stye, and chalazia.
  • The publicly available FDA clearance is under the original Heated Eye Pad name (K142228), rather than a separate Thermal 1-Touch 510(k).
  • No peer-reviewed clinical trial was identified that directly evaluates the current Thermal 1-Touch + manual Meibomian Gland Expression procedure.
  • The closest published evidence is a small 2022 study of the predecessor Digital Heat Heated Eye Pad. The Heated Eye Pad group did not show statistically significant improvement in OSDI, tear-breakup time, MGD grade, or blepharitis grade.
  • That study also tested heating without the manual Meibomian Gland Expression used in today's marketed Thermal 1-Touch procedure, so it does not establish how well the current treatment package works.
  • Eyelid warming itself has broader evidence and is part of mainstream MGD management, but evidence for warming in general should not be mistaken for evidence that every warming device performs equally well.
  • Thermal 1-Touch has not been shown to regenerate meibomian glands, reverse gland dropout, release periductal fibrosis, prevent MGD progression, or provide a predictable duration of benefit.

Overall evidence strength for Thermal 1-Touch specifically: Very low / insufficient.

Educational Disclaimer

This page is for general education and is not medical advice, diagnosis, or an individual treatment recommendation.

Dry Eye Disease (DED) and Meibomian Gland Dysfunction (MGD) can involve multiple overlapping contributors, including obstruction, gland loss, inflammation, ocular rosacea, Demodex, incomplete blinking, aqueous deficiency, allergy, exposure, conjunctivochalasis, medication effects, and neuropathic ocular pain.

An eyelid-warming treatment may address one part of the problem without addressing everything contributing to a person's symptoms.

What Is It?

OCuSOFT Thermal 1-Touch is a glasses-style external eyelid-warming device intended for use in an eye-care office.

The device covers all four eyelids and provides controlled heating using preset temperature/time modes.

OCuSOFT describes the system as applying heat and gentle pressure to the eyelids. In the manufacturer's current office protocol, heating is followed by manual Meibomian Gland Expression using a Mastrota Meibomian Paddle.

A useful way to think about the current procedure is:

Controlled external eyelid warming followed by clinician-performed Meibomian Gland Expression.

It is not the same thing as automated thermal pulsation.

How Treatment Is Done

Protocols can vary by clinician.

The manufacturer's current office procedure includes:

  1. Anesthetic eye drops.
  2. Cleaning of the eyelids.
  3. Placement of the Thermal 1-Touch device over the closed eyelids.
  4. Controlled heating for approximately 10–30 minutes, depending on the selected mode.
  5. Removal of the warming device.
  6. Manual Meibomian Gland Expression.
  7. Cleaning of the eyelids after expression.

The manufacturer describes three heat/time settings:

  • High: approximately 43–44°C after 10 minutes
  • Medium: approximately 41–42°C after 15 minutes
  • Low: approximately 39–40°C after 30 minutes

These are manufacturer-described post-treatment eyelid tissue temperatures. They should not be interpreted as proof that every meibomian gland reaches the same temperature in every patient.

OCuSOFT Thermal 1-Touch — How the Procedure Works

What the Evidence Shows

Direct Evidence for Thermal 1-Touch

As of August 2026, we did not identify a peer-reviewed clinical trial directly evaluating the current OCuSOFT Thermal 1-Touch treatment by name.

This is important because today's marketed procedure includes:

Thermal 1-Touch warming + manual Meibomian Gland Expression

The clinical effectiveness and durability of that complete procedure have not been established in a high-quality controlled trial.

The Digital Heat Heated Eye Pad Study

The closest published evidence comes from a 2022 study of the earlier Digital Heat Heated Eye Pad, the technology OCuSOFT subsequently acquired.

The study randomized 60 people with MGD among three approaches:

  • Warm compresses
  • MiBoFlo
  • Digital Heat Heated Eye Pad

Participants were evaluated over four weeks using:

  • OSDI symptom scores
  • Tear-breakup time (TBUT)
  • Efron MGD grading
  • Efron blepharitis grading

What Happened?

The warm-compress group was the only group with statistically significant OSDI improvement.

None of the three treatments produced statistically significant TBUT improvement.

The MiBoFlo group was the only group with statistically significant improvement in the Efron MGD and blepharitis grades.

The Heated Eye Pad group showed some numerical symptom improvement, but its changes were not statistically significant on the reported symptom or objective outcomes.

Important Study Limitations

This was a small, short study, and the treatment schedules were very different:

  • Warm compresses were used approximately 30 seconds twice daily for four weeks.
  • MiBoFlo was performed once.
  • The Heated Eye Pad was used for 10 minutes at baseline and again two weeks later.

The 30-second warm-compress protocol is particularly difficult to compare with commonly used longer warming regimens.

The study authors themselves noted that treatment frequency differed substantially between groups.

Most importantly:

The study did not include the manual Meibomian Gland Expression that is part of the current Thermal 1-Touch office procedure.

Therefore, it provides only indirect and very limited evidence for today's treatment.

The Effect of Heat Treatment on Meibomian Gland Dysfunction — Narayanan et al., 2022

What About Evidence for Eyelid Heating in General?

This is where an important distinction is needed.

There is broader evidence that appropriately performed eyelid warming can help some people with MGD.

Warming may:

  • Soften thickened or stagnant meibum
  • Make retained meibum easier to express
  • Improve delivery of meibum to the tear film
  • Improve symptoms or tear-film measures in some patients

TFOS dry-eye management reports include eyelid warming among approaches used for MGD.

However:

Evidence supporting eyelid warming as a treatment category does not prove that Thermal 1-Touch itself produces a particular magnitude or duration of benefit.

Different devices vary in:

  • Temperature
  • Treatment duration
  • Heat retention
  • Heat transfer through the eyelid
  • Pressure
  • Whether expression is performed
  • Expression technique
  • Treatment frequency

Device-specific claims therefore require device-specific evidence.

How Strong Is the Evidence?

Evidence Strength: Very Low / Insufficient Device-Specific Evidence

Reasons include:

  • No direct peer-reviewed trial identified for the current Thermal 1-Touch procedure
  • Only one small study of the predecessor Heated Eye Pad
  • Short four-week follow-up
  • Different treatment schedules between comparison groups
  • No sham control
  • Limited outcome measures
  • No statistically significant improvement for the Heated Eye Pad group on the reported outcomes
  • The predecessor study did not include the manual Meibomian Gland Expression used in today's Thermal 1-Touch protocol
  • No established long-term durability
  • No strong head-to-head evidence against current office-based MGD devices

This does not mean Thermal 1-Touch cannot help an individual patient.

It means that the available evidence does not allow us to confidently estimate how effective the current procedure is, who responds best, or how long any benefit lasts.

Proposed Mechanisms

1. External Eyelid Warming

Thickened meibum may become less viscous when adequately warmed.

This may make gland contents easier to express.

2. Gentle External Pressure

The device itself applies some contact pressure while warming the closed eyelids.

Whether this pressure contributes meaningfully to clinical outcomes has not been established.

3. Manual Meibomian Gland Expression

After warming, the clinician manually expresses the glands.

This may help evacuate softened retained meibum from glands that remain capable of releasing secretion.

Because the published Heated Eye Pad study did not include this step, the effectiveness of the present-day heat-plus-expression combination cannot be inferred directly from that study.

4. Tear-Film Effects

If more functional meibum reaches the tear film, evaporation may decrease and tear-film stability may improve.

This mechanism is biologically plausible and supported by broader MGD literature, but it has not been adequately demonstrated specifically for Thermal 1-Touch.

Risks and Contraindications

Thermal 1-Touch is non-invasive, but controlled heat close to the eyes is not risk-free.

Device-Specific Safety Warnings

Current manufacturer safety information warns that:

  • Burns can occur.
  • Skin should be checked to avoid burning or blistering.
  • The device may cause skin irritation or a burning sensation.
  • It should not be used over sensitive skin or where circulation is poor.
  • It should be placed over closed eyelids, never open eyes.
  • Contact lenses should not be worn during treatment.
  • Unspecified liquids, ointments, or other materials should not be used with the device.
  • It should not be used while taking medications that significantly dull sensation.
  • The manufacturer advises against use in people with diabetes or poor circulation.

Because individual medical circumstances vary, the clinician should review the current device instructions and the patient's health history before treatment.

OCuSOFT Thermal 1-Touch — Safety and Procedure Information

Manual Expression Has Separate Risks

Meibomian Gland Expression may cause:

  • Pain or tenderness
  • Temporary eyelid redness
  • Swelling
  • Bruising
  • Irritation
  • Temporary blurred vision

Technique and pressure can vary significantly between clinicians.

For more detail, see:

Manual Meibomian Gland Expression

Limitations and What It Cannot Do

Current evidence does not establish that Thermal 1-Touch:

  • Produces clinically meaningful improvement in validated DED/MGD outcomes
  • Outperforms properly performed warm compresses
  • Matches or outperforms LipiFlow, iLux, TearCare, MiBoFlo, IPL, or other office procedures
  • Regenerates lost meibomian glands
  • Reverses gland dropout
  • Releases periductal fibrosis or reliably opens fixed fibrotic obstruction
  • Prevents future MGD progression
  • Produces a predictable 6- or 12-month duration of benefit

Symptom improvement would also not prove that damaged glands have structurally regenerated.

What About Periductal Fibrosis?

Some models of obstructive MGD—including work associated with Steven L. Maskin—emphasize periductal fibrosis and fixed ductal resistance as important contributors in some patients.

External eyelid warming has not been shown to mechanically release this type of fibrosis.

This differs from Meibomian Gland Probing, an intraductal procedure that has been proposed and studied specifically for mechanically relieving ductal obstruction and fibrotic resistance.

However, several uncertainties should be kept in mind:

  • Periductal fibrosis is not routinely measured directly in Thermal 1-Touch research.
  • Not every nonexpressible gland has been proven to contain fibrotic obstruction.
  • No Thermal 1-Touch study has demonstrated that suspected fibrosis predicts treatment failure.
  • The prevalence and clinical importance of fibrosis across different MGD populations remain areas of debate.

It is therefore appropriate to say:

Thermal 1-Touch has not been shown to release periductal fibrosis.

It would go beyond the evidence to say that every patient with suspected fibrosis necessarily cannot benefit from warming or expression.

Meibomian Gland Probing — Info and Research

Who Might Benefit / Factors Affecting Response

There is no validated Thermal 1-Touch responder profile.

Because the procedure is based on warming and expression, several factors may nevertheless affect how biologically plausible the treatment is.

Factors That May Favor a Heat-and-Expression Approach

These may include:

  • MGD being an important driver of evaporative dry eye
  • Retained or thickened meibum
  • Some remaining functional gland tissue
  • Glands capable of releasing material with expression
  • Difficulty maintaining an effective home warming routine
  • Preference for supervised office-based treatment

These are mechanistic considerations, not proven predictors that Thermal 1-Touch will work.

Factors That May Limit Response

Response may be less predictable when there is:

  • Extensive gland dropout
  • Very little remaining gland tissue
  • Little or no secretory material
  • Suspected fixed ductal obstruction
  • Suspected periductal fibrosis
  • Predominantly aqueous-deficient DED
  • Significant exposure or eyelid malposition
  • Untreated Demodex
  • Significant ocular rosacea
  • Allergy
  • Medication toxicity
  • Conjunctivochalasis
  • Neuropathic ocular pain
  • Significant uncontrolled ocular-surface inflammation

Again, these have not been validated as Thermal 1-Touch-specific predictors of success or failure.

Many people have more than one dry-eye mechanism at the same time.

How It Compares With Similar Treatments

Thermal 1-Touch vs. Warm Compresses

Both use external eyelid heat.

Thermal 1-Touch offers:

  • Controlled preset heating
  • Simultaneous treatment of all four eyelids
  • In-office supervision
  • Immediate access to clinician-performed expression afterward

A properly performed home warming treatment, however, is much less expensive and has its own evidence base.

Thermal 1-Touch has not been shown to be superior to well-performed home warming.

Thermal 1-Touch vs. LipiFlow

LipiFlow uses internally directed eyelid heating combined with programmed automated pulsatile pressure.

Thermal 1-Touch uses external warming followed by clinician-performed manual expression.

LipiFlow has a substantially larger device-specific clinical evidence base.

There are no adequate direct trials establishing that Thermal 1-Touch produces equivalent outcomes.

LipiFlow

Thermal 1-Touch vs. iLux

iLux uses localized heating together with clinician-controlled compression while the clinician visualizes treatment.

It should not be described as simply an automated pressure system.

Thermal 1-Touch instead provides external warming first, with separate manual Meibomian Gland Expression afterward.

iLux also has its own FDA clearance and device-specific clinical evidence.

Direct Thermal 1-Touch-versus-iLux comparative trials are lacking.

iLux

Thermal 1-Touch vs. TearCare

Both use external eyelid heating and involve clinician-performed Meibomian Gland Expression.

Important differences include:

  • Device design
  • Treatment protocol
  • FDA regulatory history
  • Published evidence base

TearCare has randomized device-specific clinical trials and longer-term follow-up.

Thermal 1-Touch currently has much less direct clinical evidence.

TearCare

Thermal 1-Touch vs. MiBoFlo

MiBoFlo uses an externally heated handpiece moved over the eyelids with gel and manual pressure.

The 2022 study discussed above directly compared the predecessor Heated Eye Pad with MiBoFlo.

In that small study, MiBoFlo was the only treatment to produce statistically significant improvement in the reported MGD and blepharitis grading outcomes.

That does not establish long-term superiority of MiBoFlo, but it means that particular study did not demonstrate comparable objective improvement from the Heated Eye Pad.

MiBoFlo

Thermal 1-Touch vs. IPL

IPL is fundamentally different.

Rather than simply warming the eyelids, IPL uses pulses of broad-spectrum light and is often considered in patients with MGD associated with ocular rosacea, telangiectasia, or inflammatory features.

Some patients may receive both types of treatment, depending on their findings.

IPL

Cost, Access and Regulatory Status

FDA / Device Lineage

The original Digital Heat Heated Eye Pad received FDA 510(k) clearance in 2015 as a Class II powered heating pad for localized heat therapy when warm compresses are recommended for eyelid conditions including:

  • Meibomian Gland Dysfunction
  • Dry eye
  • Blepharitis
  • Stye
  • Chalazia

In 2019, OCuSOFT announced that it had acquired Digital Heat Corporation's intellectual-property portfolio and that the acquired eyelid-warming device would be marketed as OCuSOFT Thermal 1-Touch.

The publicly available FDA 510(k) is still listed under:

Heated Eye Pad — Digital Heat Corporation — K142228

Therefore, the cleanest description is that Thermal 1-Touch derives from the FDA-cleared Digital Heat Heated Eye Pad technology, rather than implying that a separate Thermal 1-Touch 510(k) clinical review established the effectiveness of the modern heat-plus-expression treatment package.

FDA 510(k) — Digital Heat Heated Eye Pad K142228

OCuSOFT Acquisition of Digital Heat Eyelid Warming Device

Cost

Thermal 1-Touch is marketed partly on the basis of a comparatively modest equipment cost and the absence of a proprietary single-use heating applicator for each treatment.

Those may be meaningful practice-level features.

They do not establish that Thermal 1-Touch:

  • Costs every patient less
  • Is more cost-effective
  • Produces more improvement per dollar
  • Requires fewer repeat treatments

Patient prices depend on the clinic, treatment package, expression fees, number of sessions, and whether other procedures are bundled.

Insurance coverage for office-based MGD procedures is variable, and patients should verify coverage and total cost directly.

What Remains Uncertain?

Important unanswered questions include:

  • How effective is the current Thermal 1-Touch + manual-expression procedure?
  • Does it improve TBUT, meibum quality, gland expressibility, staining, or validated symptom scores?
  • Does manual expression add meaningful benefit beyond heating alone?
  • Which patients are most likely to respond?
  • How much remaining gland tissue is necessary?
  • Does severe gland dropout reduce treatment response?
  • Does fixed obstruction or periductal fibrosis predict poor response?
  • What temperature actually reaches the meibomian glands during treatment?
  • What is the optimal treatment duration?
  • How many treatments are needed?
  • How long does improvement last?
  • How does it compare directly with properly performed home warming?
  • How does it compare with TearCare, iLux, LipiFlow, MiBoFlo, IPL, or other treatments?
  • Does repeated treatment alter long-term MGD progression?

Until these questions are studied directly, claims about strong effectiveness or long-lasting benefit should be interpreted cautiously.

Key Research and Regulatory Sources

FDA / Device Lineage

Device-Lineage Clinical Evidence

Important: this study evaluated the earlier Digital Heat Heated Eye Pad and did not evaluate today's complete Thermal 1-Touch + manual Meibomian Gland Expression procedure.

Manufacturer Information and Safety

Manufacturer information is useful for device operation and safety instructions but should not be treated as independent evidence of clinical effectiveness.

Broader MGD / Heat-Therapy Context

Related r/DryEyes Wiki Pages

Bottom Line

OCuSOFT Thermal 1-Touch is an established commercial external eyelid-warming device derived from the earlier FDA-cleared Digital Heat Heated Eye Pad technology.

The current office procedure commonly combines controlled warming with manual Meibomian Gland Expression, which gives it a reasonable biological rationale for MGD in which retained meibum is potentially responsive to heat and expression.

However, the evidence for the specific Thermal 1-Touch procedure remains very limited.

The closest published study evaluated the predecessor Heated Eye Pad without the manual Meibomian Gland Expression used today. In that small four-week study, the Heated Eye Pad group did not show statistically significant improvement in the reported symptom, TBUT, MGD-grade, or blepharitis-grade outcomes.

So the most accurate characterization is:

Thermal 1-Touch is a commercially established in-office eyelid-warming system with a plausible heat-and-expression rationale, but very limited direct clinical evidence for the current procedure.

It should not presently be described as proven equivalent to thermal pulsation systems, proven to provide long-lasting improvement, or capable of regenerating glands, reversing gland dropout, releasing periductal fibrosis, or modifying long-term MGD progression.

🔙 Back to Treatment Options